1. Introduction {#sec0005}
===============

The commercialization of any novel ingredient/foodstuff is requisitely accompanied by safety tests. The present journal article discusses bacterial reverse mutation (Ames test) and *in vitro* human peripheral blood lymphocyte (HPBL) micronucleus assays utilizing ClearTaste, a novel taste modulating powder made through the culturing of *Cordyceps sinensis*, as a test article. ClearTaste was discovered at MycoTechnology, Inc. in July 2014.

Taste modulation has been the subject of much interest over the decades in part due to the discipline's important economic implications in driving consumer preference. While the perception and modulation of all five conventional tastes have been intensely investigated and better understood over the last 2--3 decades, food science has taken particularly extensive measures to identify novel bitter blockers, an effort perhaps only matched by the investigation of sweetness intensifiers \[[@bib0005], [@bib0010], [@bib0015], [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040]\]. ClearTaste is unique as a bitter blocker being that it is derived through the culturing of a fungus. When used at proper concentrations (typically \<50 ppm) ClearTaste can also mitigate sour, metallic and lingering off tastes. ClearTaste's functionality makes it highly alluring to the food and flavor industry, heightening the pertinence of this journal article.

The purpose of reverse mutation and micronucleus assays are, respectively, to investigate the extent to which a test article is mutagenic or genotoxic/induces chromosome instability. Reverse mutation assays analyze frameshift and basepair substitution mutations in *Salmonella typherium* and *Eschericia coli*. Micronucleus assays monitor the extent that micronuclei, small cytoplasmic membrane bodies carrying pieces of or an entire chromosome due to a malfunctioning anaphase, form when exposed to a test article. Known mutagens and micronuclei inducers are used as control articles in each test, respectively. These tests determine an important aspect of food safety and are essential to informing potential consumers about the nature of novel food. Some physicochemical properties and the proximate analysis of ClearTaste are shown in [Table 1](#tbl0005){ref-type="table"}, [Table 2](#tbl0010){ref-type="table"}.Table 1Physicochemical Properties of ClearTaste.Table 1Solubility∼99.5% soluble at up to 6% ClearTaste m/vDensity0.5 g/LpH[a](#tblfn0005){ref-type="table-fn"}4.3Melting Point193--205 °CIgnitabilityNot ignitable[^1]Table 2ClearTaste Proximate Composition.Table 2PropertyConcentration (%)Moisture (vacuum oven)1.8Protein1.3Fat (acid hydrolysis)0.7Ash2.6Carbohydrates (by difference)93.6[^2]

2. Materials and methods {#sec0010}
========================

2.1. Statement of GLP validation {#sec0015}
--------------------------------

The bacterial reverse mutation and *in vitro* HBPL micronucleus assays were conducted by a third party according to Good Laboratory Practice as parameterized by the United States Food and Drug Administration. Detailed methods for the execution of these procedures and be found in the List of References, with certain references discussing the bacterial reverse mutation assay \[[@bib0045], [@bib0050], [@bib0055]\] and others discussing the micronucleus assay \[[@bib0060], [@bib0065], [@bib0070]\].

2.2. Bacterial reverse mutation assay {#sec0020}
-------------------------------------

### 2.2.1. Test system {#sec0025}

The tester strains used were the *Salmonella typhimurium* histidine auxotrophs TA98, TA100, TA1535 and TA1537 as described by Ames et al. \[[@bib0045]\] and *Escherichia coli* WP2 *uvr*A as described by Green and Muriel \[[@bib0050]\].

Tester strains TA98 and TA1537 are reverted from histidine dependence (auxotrophy) to histidine independence (prototrophy) by frameshift mutagens. Tester strain TA1535 is reverted by mutagens that cause basepair substitutions. Tester strain TA100 is reverted by mutagens that cause both frameshift and basepair substitution mutations. Specificity of the reversion mechanism in *E. coli* is sensitive to basepair substitution mutations rather than frameshift mutations. *Salmonella* tester strains were derived from Dr. Bruce Ames' cultures; *E*. *coli* tester strains were from the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland. Historical data for the test system is provided in [Table 3](#tbl0015){ref-type="table"}. Historical data are more important in micronucleus assays for determining outcomes of the assay but are included herein for the Ames assay for those interested.Table 3Historical Negative and Positive Control Values for Reverse Mutation Assay, 2014.Table 3ActivationStrainControlNoneRat LiverMeanSDMinMax95% CL[a](#tblfn0010){ref-type="table-fn"}MeanSDMinMax95% CL\*TA98Neg1655426--2624755310--38Pos2322585726914001651091382TA100Neg94146615266--122102186316466--138Pos68117621317676812591862793TA1535Neg1142313--191352363--23Pos58622616250911799231060TA1537Neg731191--13941231--17Pos411355322921725210562WP2 uvrANeg25776211--39288105512--44Pos37612399102630210291687[^3]

### 2.2.2. Preparation of tester strain {#sec0030}

Overnight cultures were prepared by inoculating from the appropriate frozen permanent stock into a vessel containing 30--50 mL of culture medium. To assure that cultures were harvested in late log phase, the length of incubation was controlled and monitored. Following inoculation, each flask was placed in a shaker/incubator programmed to begin shaking at 125--175 rpm and incubating at 37 ± 2 °C for approximately 12 h before the anticipated time of harvest. Each culture was monitored spectrophotometrically for turbidity and was harvested at a percent transmittance yielding a titer of greater than or equal to 0.3 × 10^9^ cells/mL. The actual titers were determined by viable count assays on agar plates.

### 2.2.3. Exogenous metabolic activation {#sec0035}

Aroclor™ 1254-induced rat liver S9 was used as the metabolic activation system. The S9 was prepared from male Sprague-Dawley rats that were injected intraperitoneally with Aroclor 1254 (200 mg/mL in corn oil) at a dose of 500 mg/kg, five days before sacrifice. The S9 (Lot No. 3586, Exp. Date: 09 February 2018) was purchased commercially from MolTox (Boone, NC). Upon receipt the S9 was stored at −60 °C or colder until use. Each bulk preparation of S9 was assayed for its ability to metabolize benzo(a)pyrene and 2‐aminoanthracene to forms mutagenic to Salmonella typhimurium TA100. The S9 mix was prepared on the day of use with 4 mM β‐nicotinamide‐adenine dinucleotide phosphate, 5 mM glucose-6-phosphate, 33 mM potassium chloride, 8 mM magnesium chloride, 100 mM pH 7.4 phosphate buffer and 10% (v/v) S9 homogenate. The Sham mix, containing 100 mM phosphate buffer at pH 7.4, was also prepared on the day of use.

### 2.2.4. Frequency and route of administration {#sec0040}

The test system was exposed to ClearTaste via the plate incorporation methodology originally described by Ames et al. \[[@bib0045]\] and updated by Maron and Ames \[[@bib0055]\]. Water was the vehicle of choice. ClearTaste formed workable suspensions in water at concentrations of approximately 1--50 mg/mL with sonication at 37 °C for 70 min.

### 2.2.5. Preliminary toxicity assay {#sec0045}

The preliminary toxicity assay was used to establish the dose‐range over which ClearTaste would be assayed. TA98, TA100, TA1535, TA1537 (*Salmonella typherium*) and WP2 *uvr*A (*Escherichia coli*) were exposed to the vehicle alone and ten dose levels of ClearTaste, with a single plate/condition, on selective minimal agar in the presence and absence of Aroclor‐induced rat liver S9. Dose levels for the mutagenicity assay were based upon the absence of post-treatment toxicity.

### 2.2.6. Mutagenicity assay {#sec0050}

TA98, TA100, TA1535, TA1537 and WP2 *uvr*A were exposed to water alone, the positive controls 2-nitrofluorene, sodium azide, 9-aminoacridine, methyl methanesulfonate and five dose levels of ClearTaste, in triplicate, in the absence of Aroclor‐induced rat liver S9 and in its presence was identically treated but for the control only having been 2-aminoanthracene.

### 2.2.7. Confirmatory mutagenicity assay {#sec0055}

TA98, TA100, TA1535, TA1537 and WP2 *uvr*A were exposed to water alone, positive controls 2-nitrofluorene, sodium azide, 9-aminoacridine, methyl methanesulfonate and 2-aminoanthracene and five dose levels of ClearTaste, in triplicate, in the presence and absence of Aroclor‐induced rat liver S9.

### 2.2.8. Treatment of test system {#sec0060}

To confirm the sterility of the S9 and Sham mixes, a 0.5 mL aliquot of each was plated on selective agar. To confirm the sterility of ClearTaste and the water, all ClearTaste dose levels and the vehicle used in each assay were plated on selective agar with an aliquot volume equal to that used in the assay. These plates were incubated under the same conditions as the assay.

One‐half (0.5) milliliter of S9 or Sham mix, 100 μL of tester strain (cells seeded) and 100 μL of vehicle or ClearTaste dilution were added to 2 mL of Petri plates with 0.8% m/v BBL select agar, 0.5% m/w sodium chloride, 50 mM each of L-histidine, D-biotin and L-tryptophan at 45 ± 2 °C. When plating the positive controls, the ClearTaste aliquot was replaced by a 50 μL aliquot of appropriate positive control. After vortexing, the mixture was overlaid onto the surface of 25 mL of minimal bottom agar containing 0.8% m/v BBL select agar and 1.5% mv Vogel-Bonner minimal medium E. After the overlay had solidified, the plates were inverted and incubated for 48--72 h at 37 ± 2 °C. Plates that were not counted immediately following the incubation period were stored at 2--8 °C until colony counting could be conducted.

### 2.2.9. Criteria for determination of a valid test {#sec0065}

The following criteria must be met for the mutagenicity and confirmatory mutagenicity assays to be considered valid:

All *Salmonella* tester strain cultures must demonstrate the presence of the deep rough mutation (*rfa*) and the deletion in the *uvr*B gene. Cultures of tester strains TA98 and TA100 must demonstrate the presence of the pKM101 plasmid R‐factor. All WP2 *uvr*A cultures must demonstrate the deletion in the *uvr*A gene.

All cultures must demonstrate the characteristic mean number of spontaneous revertants in the vehicle controls as follows: TA98, 10--50; TA100, 80--240; TA1535, 5--45; TA1537, 3--21; WP2 *uvr*A, 10--60.

To ensure that appropriate numbers of bacteria are plated, tester strain culture titers must be greater than or equal to 0.3 × 10^9^ cells/mL.

The mean of each positive control must exhibit at least a 3 fold increase in the number of revertants over the mean value of the respective vehicle control.

A minimum of three non‐toxic dose levels is required to evaluate assay data. A dose level is considered toxic if one or both of the following criteria are met: (1) A \> 50 % reduction in the mean number of revertants per plate as compared to the mean vehicle control value. This reduction must be accompanied by an abrupt dose‐dependent drop in the revertant count. (2) At least a moderate reduction in the background lawn (background code 3, 4 or 5).

### 2.2.10. Evaluation of test results {#sec0070}

For ClearTaste to be mutagenic it must cause a dose-related increase in the mean revertants/plate of at least one tester strain over a minimum of two increasing concentrations of ClearTaste.

Data sets were judged positive if the increase in mean revertants at the peak of the dose response was equal to or greater than 2 times the mean vehicle control value.

An equivocal response is a biologically relevant increase in a revertant count that partially meets the criteria for evaluation as positive. This could be a dose-responsive increase that does not achieve the respective threshold cited above or a non-dose responsive increase that is equal to or greater than the respective threshold cited. A response was evaluated as negative if it was neither positive nor equivocal.

2.3. In vitro human peripheral blood lymphocyte micronucleus assay {#sec0075}
------------------------------------------------------------------

### 2.3.1. Characterization of test and control articles {#sec0080}

The vehicle used to deliver ClearTaste to the test system was water supplied by Gibco, CAS \# 7732-18-5. Dilutions were prepared immediately before use and delivered to the test system at room temperature under filtered light. Controls besides water were cyclophosphamide and vinblastine.

Vinblastine was dissolved in sterile distilled water to stock concentration of 0.0005, 0.00075, and 0.001 mg/mL (final concentrations of 5, 7.5, and 10 ng/mL, respectively) as the positive control in the non-activated test system. Cyclophosphamide was dissolved and diluted in sterile distilled water to stock concentrations of 0.25, 0.5 and 0.75 mg/mL (final concentrations of 2.5, 5 and 7.5 μg/mL, respectively) for use as the positive control article in the S9-activated test system. Since the non-activated and S9-activated treatments were tested concurrently, the positive control for the non-activated 4 h exposure groups was eliminated. For each positive control article, one dose level exhibiting a sufficient number of scorable cells was selected for analysis. The vehicle for ClearTaste was used as the vehicle control for each treatment group.

Cytochalasin B was dissolved in DMSO to a stock concentration of 2 mg/mL. It was used at 6 μg/mL concentration to block cytokinesis.

### 2.3.2. Test system {#sec0085}

HPBLs were obtained from healthy, non-smoking individuals. For the preliminary toxicity work a 22 year old female had HPBLs collected on April 4th, 2016. For the micronucleus assay a 29 year old female donated HPBLs on April 19th, 2016.

The donors had no recent history of radiotherapy, viral infection or the administration of drugs. This system has been demonstrated to be sensitive to the genotoxicity test for detection of micronuclei of a variety of chemicals according to Clare et al. \[[@bib0060]\].

### 2.3.3. Preparation of target cells {#sec0090}

HPBLs were cultured in complete medium (RPMI‐1640 containing 15% fetal bovine serum, 2 mM L‐glutamine, 100 units penicillin, 100 μg/mL streptomycin) by adding 0.5 mL heparinized blood to a centrifuge tube containing 5 mL of complete medium with 2% phytohemagglutinin. The cultures were incubated under standard conditions (37 ± 1 °C in a humidified atmosphere of 5 ± 1% CO~2~ in air) for 44--48 h.

### 2.3.4. Exogenous metabolic activation system {#sec0095}

Aroclor 1254-induced rat liver S9 was used as the metabolic activation system. The S9 was prepared from male Sprague-Dawley rats that were injected intraperitoneally with Aroclor 1254 (200 mg/mL in corn oil) at a dose of 500 mg/kg, five days before sacrifice. The S9 (Lot No. 3563, Exp. Date: 15 Dec 2017) was purchased commercially from MolTox (Boone, NC). Upon receipt the S9 was stored at −60 °C or colder until used. Each bulk preparation of S9 was assayed for its ability to metabolize benzo(a)pyrene and 2‐aminoanthracene to forms mutagenic to *Salmonella typhimurium* TA100.

The S9 mix was prepared on the day of use and contained 1 mM β‐nicotinamide‐adenine dinucleotide phosphate, 1 mM glucose-6-phosphate, 6 mM potassium chloride, 2 mM magnesium chloride and 20 μL/mL S9 homogenate.

### 2.3.5. Preliminary cytotoxicity test {#sec0100}

HPBLs were exposed to water alone and nine dose levels of ClearTaste with half-log dose spacing using single cultures. Precipitation of test article dosing solution in the treatment medium was determined using the unaided eye at the beginning and conclusion of treatment. Dose levels for the micronucleus assay were based upon visible precipitate in the treatment medium at the conclusion of the treatment period. In treatment groups with lack of cytotoxicity or visible precipitate in the treatment medium, the highest dose tested was 2000 μg/mL.

### 2.3.6. Micronucleus assay {#sec0105}

Based on the results of the preliminary toxicity test, the doses selected for testing in the micronucleus assay were 100, 250, 500, 1000 and 2000 μg/mL in a non-activated treatment condition for 4 and 24 h (with 4 and 0 h recovery times, respectively) in the presence of Aroclor-induced rat liver S9 for 4 h with 20 h recovery time.

Precipitation of the test article dosing solution in the treatment medium was determined using the unaided eye at the beginning and conclusion of treatment. The highest dose evaluated for the micronuclei was selected based on visible precipitate at the end of the treatment period in the 4 h (-S9) and 4 h (+S9) treatments and by the highest dose tested in the micronucleus assay (2000 μg/mL) in the 24 h (-S9) treatment. Two additional doses were included in the evaluation of micronuclei.

### 2.3.7. Treatment of target cells (Preliminary toxicity test and micronucleus assay) {#sec0110}

After the 4 h treatment in the non-activated and the S9-activated studies, the cells were centrifuged, the treatment medium was aspirated, washed with calcium and magnesium free phosphate buffered saline (CMF-PBS), re-fed with complete medium containing cytochalasin B at 6.0 μg/mL and returned to the incubator under standard conditions. For the 24 h treatment in the non-activated study, cytochalasin B (6.0 μg/mL) was added at the beginning of the treatment.

### 2.3.8. Collection of cells (Preliminary toxicity test and micronucleus assay) {#sec0115}

Cells were collected after being exposed to cytochalasin B for 24 h (±30 min), 1.5--2 normal cell cycles, to ensure identification and selective analysis of micronucleus frequency in cells that have completed one mitosis evidenced by binucleated cells as according to Fenech and Morley \[[@bib0065]\]. The cytochalasin B exposure time for the 4 h treatment in the non-activated and the S9-activated studies was 20 h (±30 min).

Cells were collected by centrifugation, swollen with 0.075 M KCl, washed with fixative (methanol: glacial acetic acid, 25:1 v/v), capped and may be stored overnight or longer at 2--8 °C. To prepare slides, the cells were collected by centrifugation and the cells were resuspended in fresh fixative. The suspension of fixed cells was applied to glass microscope slides and air-dried.

### 2.3.9. Statistical analysis {#sec0120}

Statistical analysis was performed using the Fisher\'s exact test (p ≤ 0.05) for a pairwise comparison of the percentage of micronucleated cells in each treatment group with that of the vehicle control. The Cochran-Armitage trend test was used to assess dose-responsiveness.

### 2.3.10. Criteria for determination of a valid test {#sec0125}

#### 2.3.10.1. Vehicle controls {#sec0130}

The frequency of cells with micronuclei should ideally be within the 95% control limits of the distribution of the historical negative control database, taken in 2014 and shown in [Table 3](#tbl0015){ref-type="table"}.If the concurrent negative control data fall outside the 95% control limits, they may be acceptable as long as these data are not extreme outliers (indicative of experimental or human error). Historical data for non-S9 activated and S9 activated systems are shown in [Table 4](#tbl0020){ref-type="table"}, [Table 5](#tbl0025){ref-type="table"}.Table 4Historical Negative and Positive Control Values for Non-S9 Activated Micronucleus Assay, 2013--2015.Table 4Micronucleated Binucleated Cells (%)Negative ControtPositive Control[a](#tblfn0015){ref-type="table-fn"}4 h24 h4 h24 hMean0.360.393.771.76Standard Deviation0.230.311.660.8695% Control Limits0.00--0.820.00--1.010.46--7.080.04--3.48Range[b](#tblfn0020){ref-type="table-fn"}0.05--1.430.10--2.001.00--10.100.50--5.70[^4][^5]Table 5Historical Negative and Positive Control Values for S9 Activated Micronucleus Assay, 2013--2015.Table 5Micronucleated Binucleated Cells (%)Negative ControlPositive Control[a](#tblfn0025){ref-type="table-fn"}Mean0.331.51Standard Deviation0.230.5095% Control Limits0.00--0.780.50--2.51Range[b](#tblfn0030){ref-type="table-fn"}0.10--1.500.40--3.30[^6][^7]

#### 2.3.10.2. Positive controls {#sec0135}

The percentage of micronucleated cells must be significantly greater than the concurrent vehicle control (p ≤ 0.05). In addition, the cytotoxicity response must not exceed the upper limit for the assay (55%). According to the methods of its calculation as shown in [Table 7](#tbl0035){ref-type="table"}, cytotoxicity is considered substantial at 55 ± 5%, any test article yielding lower values being considered non-cytotoxic \[[@bib0065]\].

#### 2.3.10.3. Cell proliferation {#sec0140}

The CBPI of the vehicle control at harvest must be ≥1.4.

### 2.3.11. Evaluation of test results {#sec0145}

The test article was considered to have induced a positive response if at least one of the test concentrations exhibited a statistically significant increase when compared with the concurrent negative control (p ≤ 0.05), the increase was concentration-related (p ≤ 0.05) and results were outside the 95% control limit of the historical negative control data.

ClearTaste was considered to have induced a clear negative response if none of the criteria for a positive response were met.

3. Results {#sec0150}
==========

3.1. Bacterial reverse mutation assay {#sec0155}
-------------------------------------

### 3.1.1. Sterility and tester strain titer results {#sec0160}

No contaminant colonies were observed on the sterility plates for the vehicle control, the test article dilutions or the S9 and Sham mixes. Data for the tester strain titer results are shown in [Table 6](#tbl0030){ref-type="table"}.Table 6Reverse Mutation Assay Tester Strain Titer Results.Table 6ExperimentTester StrainTA98TA100TA1535TA1537WP2 uvrATiter Value (x10^9^ cells/mL)Mutagenicity Assay11.511.18.711.212.4Confirmatory Mutagenicity Assay3.04.02.46.52.6

### 3.1.2. Preliminary toxicity assay {#sec0165}

The results of the preliminary toxicity assays without and with S9 activation are presented in [Table 7](#tbl0035){ref-type="table"}, [Table 8](#tbl0040){ref-type="table"}, respectively. The tables show what ClearTaste and water concentrations were applied to each strain, the average revertant count/plate, the ratio of each ClearTaste dose to that of the water control and the background codes of each revertant count. The greatest ratio of any ClearTaste dose revertant counts to those of the water control was 1.7 for any strain in either table.Table 7Preliminary Toxicity Assay without S9 Activation.[a](#tblfn0035){ref-type="table-fn"}Table 7StrainArticleDose (μg/plate)Revertants (mean/ plate)Revertant Ratio (dose/control)Individual Revertant Colony Counts and Background CodesTA98ClearTaste5000221.422^A^ 1 NP333390.69^A^ 1 NP1000130.913^A^667110.711^A^333130.813^A^100271.727^A^66.7100.610^A^33.3191.219^A^10.0100.610^A^6.67140.914^A^Water1001616^A^TA100ClearTaste50001131.4113^A^ 1 NP3333801.080^A^ 1 NP1000891.189^A^667931.193^A^333821.082^A^1001041.3104^A^66.7991.299^A^33.3971.297^A^10.0881.188^A^6.67730.973^A^Water1008383^A^TA1535ClearTaste5000130.913^A^ 1 NP3333110.811^A^ 1 NP1000100.710^A^667110.811^A^333171.217^A^100171.217^A^66.7110.811^A^33.3110.811^A^10.080.68^A^6.6790.69^A^Water1001414^A^TA1537ClearTaste500061.06^A^ 1 NP333310.21^A^ 1 NP100050.85^A^66730.53^A^33361.06^A^10061.06^A^66.781.38^A^33.381.38^A^10.071.27^A^6.6781.38^A^Water10066^A^WP2uvrAClearTaste5000271.127^A^ 1 NP3333241.024^A^ 1 NP1000210.921^A^667220.922^A^333220.922^A^100261.126^A^66.7190.819^A^33.3160.716^A^10.0140.614^A^6.67110.511^A^Water1002424^A^[^8][^9][^10]Table 8Preliminary Toxicity Assay with S9 Activation.[a](#tblfn0040){ref-type="table-fn"}Table 8StrainArticleDose (μg/plate)Revertants (mean/ plate)Revertant Ratio (dose/control)Individual Revertant Colony Counts and Background CodesTA98ClearTaste5000160.616^A^ 1 NP3333301.130^A^ 1 NP1000180.718^A^667341.334^A^333190.719^A^100311.131^A^66.7220.822^A^33.3230.923^A^10.0240.924^A^6.67250.925^A^Water1002727^A^TA100ClearTaste5000761.076^A^ 1 NP3333881.188^A^ 1 NP1000720.972^A^667740.974^A^333951.295^A^100710.971^A^66.71051.3105^A^33.3801.080^A^10.0951.295^A^6.67821.082^A^Water1008080^A^TA1535ClearTaste5000110.811^A^ 1 NP333370.57^A^ 1 NP1000130.913^A^66780.68^A^33370.57^A^100171.217^A^66.7141.014^A^33.3181.318^A^10.0151.115^A^6.67151.115^A^Water1001414^A^TA1537ClearTaste500030.43^A^ 1 NP333371.07^A^ 1 NP100081.18^A^66771.07^A^33391.39^A^10060.96^A^66.760.96^A^33.391.39^A^10.020.32^A^6.67131.913^A^Water10077^A^WP2uvrAClearTaste5000211.221^A^ 1 NP3333251.425^A^ 1 NP1000211.221^A^667191.119^A^333160.916^A^100211.221^A^66.7241.324^A^33.3150.815^A^10.0221.222^A^6.67261.426^A^Water1001818^A^[^11][^12][^13]

### 3.1.3. Mutagenicity assay {#sec0170}

The results of the mutagenicity assays without and with S9 activation are presented in [Table 9](#tbl0045){ref-type="table"}, [Table 10](#tbl0050){ref-type="table"}, respectively. The tables show similar information to [Table 7](#tbl0035){ref-type="table"}, [Table 8](#tbl0040){ref-type="table"} but for the last section which provides data for the mutagenic controls 2-nitrofluorene, sodium azide, 9-aminoacridine and methyl methanesulfonate in [Table 5](#tbl0025){ref-type="table"} and 2-aminoanthracene in [Table 6](#tbl0030){ref-type="table"}. The greatest ratio of any ClearTaste dose revertant counts to those of the water control was 1.5. The lowest and greatest revertant ratios for any of the mutagenic controls were 10 (2-aminoanthracene) and 555 (sodium azide).Table 9Mutagenicity Assay without S9 Activation.[a](#tblfn0045){ref-type="table-fn"}Table 9StrainArticleDose (μg/plate)Revertants (mean/ plate)Standard DeviationRevertant Ratio (dose/control)Individual Revertant Colony Counts and Background CodesTA98ClearTaste50001431.215^A^ 1 NP, 17^A^ 1NP, 11^A^ 1 NP15001231.09^A^, 14^A^, 14^A^5001030.87^A^, 9^A^, 13^A^150910.89^A^, 10^A^, 8^A^501331.114^A^, 10^A^, 16^A^Water10012111^A^, 13^A^, 11^A^TA1535ClearTaste5000921.09^A^ 1 NP, 7^A^ 1 NP15001141.211^A^, 7^A^, 14^A^5001061.13^A^, 15^A^, 13^A^1501221.314^A^, 10^A^, 13^A^50911.09^A^, 8^A^, 10^A^Water100929^A^, 8^A^, 10^A^TA1537ClearTaste5000611.26^A^ 1 NP, 5^A^1 NP, 7^A^ 1 NP1500410.85^A^, 3^A^, 3^A^500611.26^A^, 6^A^, 6^A^50621.28^A^, 5^A^, 6^A^Water100533^A^, 8^A^, 3^A^WP2uvrAClearTaste50001860.915^A^ 1 NP, 25^A^ 1NP, 15A 1 NP150022101.011^A^, 24^A^, 30^A^5002891.318^A^, 33^A^, 34^A^1501940.922^A^, 15^A^, 19^A^502221.023^A^, 23^A^, 19^A^Water10021417^A^, 21^A^, 24^A^TA982NF1111249.384^A^, 128^A^, 121^A^TA100SA1555316.6524^A^, 556^A^, 586^A^TA1535SA14352448.3462^A^, 415^A^, 428^A^TA15379AAD753887577.6382^A^, 317^A^, 466^A^WP2uvrAMMS10002968214.1209^A^, 308^A^, 372^A^[^14][^15][^16][^17][^18][^19][^20]Table 10Mutagenicity Assay with S9 Activation.Table 10StrainArticleDose (μg/plate)Revertants (mean/ plate)Standard DeviationRevertant Ratio (dose/control)Individual Revertant Colony Counts and Background CodesTA98ClearTaste50002421.123^A^ 1 NP,22^A^ 1 NP, 26^A^ 1 NP15002011.021^A^, 19^A^, 21^A^5001820.919^A^, 15^A^, 19^A^1502041.015^A^, 22^A^, 23^A^501930.916^A^, 21^A^, 19^A^Water10021219^A^, 21^A^, 23^A^TA100ClearTaste50009141.095^A^ 1 NP, 89^A^ 1NP, 88^A^ 1 NP150099131.1104^A^, 100^A^, 100^A^500720.896^A^, 100^A^, 105^A^150820.971^A^, 101^A^, 82^A^Water1009188^A^, 86^A^, 89^A^TA1535ClearTaste5000830.910^A^ 1 NP, 5^A^ 1 NP,9^A^ 1 NP1500961.03^A^, 8^A^, 15^A^500720.86^A^, 6^A^, 9^A^150820.96^A^, 9^A^, 8^A^50921.07^A^, 9^A^, 10^A^Water100919^A^, 8^A^, 9^A^TA1537ClearTaste50001160.917^A^ 1 NP, 6^A^ 1 NP,11^A^ 1 NP15001341.115^A^, 16^A^, 8^A^5001130.915^A^, 10^A^, 9^A^1501411.214^A^, 15^A^, 13^A^501140.914^A^, 6^A^, 13^A^Water10012410^A^, 9^A^, 16^A^WP2uvrAClearTaste500024121.322^A^ 1 NP,13^A^ 1 NP15002041.119^A^, 17^A^, 24^A^5002051.116^A^, 19^A^, 26^A^1502521.325^A^, 23^A^, 27^A^502861.523^A^, 26^A^, 35^A^Water10019421^A^, 15^A^, 22^A^TA982AA12394211.4277^A^, 246^A^, 194^A^TA1002AA2313223.6293^A^, 310^A^, 336^A^TA15352AA181109.075^A^, 93^A^, 75^A^TA15372AA240113.336^A^, 31^A^, 52^A^WP2uvrA2AA1530410916.0206^A^, 286^A^, 421^A^[^21][^22][^23][^24]

### 3.1.4. Confirmatory mutagenicity assay {#sec0175}

The results of the confirmatory mutagenicity assay are presented in [Table 11](#tbl0055){ref-type="table"}, [Table 12](#tbl0060){ref-type="table"} which show data structured identically to [Table 7](#tbl0035){ref-type="table"}, [Table 8](#tbl0040){ref-type="table"}, [Table 9](#tbl0045){ref-type="table"}, [Table 10](#tbl0050){ref-type="table"}. The greatest revertant ratio for any ClearTaste dose in either table was 1.5.Table 11Confirmatory Mutagenicity Assay without S9 Activation.[a](#tblfn0050){ref-type="table-fn"}Table 11StrainArticleDose (μg/plate)Revertants (mean/ plate)Standard DeviationRevertant Ratio (dose/control)Individual Revertant Colony Counts and Background CodesTA98ClearTaste50001711.217^A^ 1 NP,17^A^ 1 NP, 18^A^ 1 NP15001050.77^A^, 7^A^, 16^A^5001030.77^A^, 10^A^, 13^A^1501220.913^A^, 10^A^, 13^A^501250.98^A^, 11^A^, 18^A^Water10014416^A^, 16^A^, 9^A^TA100ClearTaste50008821.090^A^ 1 NP, 87^A^ 1NP, 87^A^ 1 NP150094161.0113^A^, 79^A^, 86^A^500104131.198^A^, 75^A^, 80^A^1509781.083^A^, 95^A^, 92^A^5098161.095^A^, 80^A^, 96^A^Water100849TA1535ClearTaste50001040.86^A^ 1 NP, 9^A^ 1 NP,14^A^ 1 NP1500940.77^A^, 6^A^, 14^A^5001341.010^A^, 17^A^, 11^A^1501841.514^A^, 10^A^, 16^A^501331.015^A^, 15^A^, 14^A^Water1001349^A^, 14^A^, 17^A^TA1537ClearTaste50001011.110^A^ 1 NP,10^A^ 1 NP, 9^A^ 1 NP15001031.110^A^, 13^A^, 7^A^500911.08^A^, 10^A^, 8^A^150720.85^A^, 7^A^, 8^A^50921.07^A^, 11^A^, 8^A^Water1009514^A^, 5^A^, 8^A^WP2uvrAClearTaste50003681.327^A^ 1 NP,43^A^ 1 NP, 38^A^ 1 NP150031121.121^A^, 29^A^, 44^A^5003261.138^A^, 26^A^, 31^A^1503351.229^A^, 39^A^, 32^A^503161.125^A^, 34^A^, 35^A^Water1009514^A^, 5^A^, 8^A^TA98Water10028630^A^, 21^A^, 32^A^2NF1106367.670^A^, 141^A^, 106^A^TA100SA1715778.5779^A^, 736^A^, 630^A^TA1535SA16155647.3593^A^, 678^A^, 573^A^TA15379AAD753485338.7384^A^, 288^A^, 373^A^WP2uvrAMMS10004059914.5294^A^, 439^A^, 483^A^[^25][^26][^27][^28][^29][^30][^31]Table 12Confirmatory Mutagenicity Assay with S9 Activation.Table 12StrainArticleDose (μg/plate)Revertants (mean/ plate)Standard DeviationRevertant Ratio (dose/control)Individual Revertant Colony Counts and Background CodesTA98ClearTaste50001531.219^A^ 1 NP,13^A^ 1 NP, 14^A^ 1 NP15001040.814^A^, 6^A^, 11^A^5001030.718^A^, 15^A^, 13^A^1501220.914^A^, 16^A^, 23^A^501250.916^A^, 17^A^, 14^A^Water10013214^A^, 11^A^, 15^A^TA100ClearTaste5000109191.1131^A^ 1 NP, 97^A^ 1NP, 99^A^ 1 NP150094161.0113^A^, 79^A^, 86^A^500104131.198^A^, 75^A^, 80^A^1509781.083^A^, 95^A^, 92^A^5098161.095^A^, 80^A^, 96^A^Water10095598^A^, 89^A^, 98^A^TA1535ClearTaste50001630.819^A^ 1 NP,16^A^ 1 NP1500920.911^A^, 13^A^, 10^A^5001441.216^A^, 9^A^, 17^A^1501841.514^A^, 22^A^, 19^A^50920.810^A^, 11^A^, 7^A^Water10012416^A^, 9^A^, 11^A^TA1537ClearTaste5000630.52^A^ 1 NP,8^A^ 1 NP, 8^A^ 1 NP1500920.811^A^, 8^A^, 8^A^500950.85^A^, 15^A^, 8^A^1501130.910^A^, 15^A^, 9^A^501371.110^A^, 9^A^, 21^A^Water10012517^A^, 11^A^, 7^A^WP2uvrAClearTaste50001621.018^A^ 1 NP,15^A^ 1 NP, 15^A^ 1 NP15001931.216^A^, 21^A^, 19^A^5001961.223^A^, 22^A^, 13^A^1501641.019^A^, 11^A^, 17^A^501731.118^A^, 19^A^, 13^A^Water10016313^A^, 17^A^, 18^A^TA982AA147237536.3214^A^, 300^A^, 902^A^TA1002AA2498775.2553^A^, 556^A^, 386^A^TA15352AA189227.4106^A^, 97^A^, 65^A^TA15372AA251144.366^A^, 39^A^, 47^A^WP2uvrAMMS10004059914.5294^A^, 439^A^, 483^A^[^32][^33][^34][^35][^36][^37][^38]

3.2. Micronucleus assay {#sec0180}
-----------------------

### 3.2.1. Preliminary cytotoxicity test {#sec0185}

Results from the preliminary cytotoxicity assay are presented in [Table 13](#tbl0065){ref-type="table"}, [Table 14](#tbl0070){ref-type="table"}, [Table 15](#tbl0075){ref-type="table"}. The results include mono-, bi- and trinucleated cell counts for various ClearTatse doses, Cytokinesis Block Proliferation Index (CBPI) and cytotoxicity data. The greatest cytotoxicity for any ClearTaste dose was 28%. Cyclophosphamide and vinblastine provide maximum cytotoxicity values of 59% and 71%, respectively. Doses having visible precipitate are indicated.Table 13Preliminary Cytotoxicity Assay Using ClearTaste in the Absence of Exogenous Metabolic Activation, 4 h Treatment and 24 h Harvest.Table 13Test ArticleTreatmentTotal \#Count/Total CellsCBPI^a^Cytotoxicity^a^ (%)ConditionCells\# Nuclei/Cell(μg/mL)Counted(1 2 \> 2)Water500125335401.830ClearTaste0.2500165320151.700160.6500150308421.78462500181273461.730126500207272211.6282420500248240121.5283660500218245371.63823200500247234191.54434600500267215181.502402000^b^495223245271.60427[^39][^40][^41][^42]Table 14Preliminary Cytotoxicity Assay Using ClearTaste in the Presence of Exogenous Metabolic Activation, 4 h Treatment and 24 h Harvest.Table 14Test ArticleTreatment Condition (μg/mL)Total \# Cells CountedCount/Total Cells \# Nuclei/Cell (1 2 \> 2)CBPI[a](#tblfn0055){ref-type="table-fn"}Cytotoxicity[a](#tblfn0055){ref-type="table-fn"} (%)Water500195293121.634ClearTaste0.2500221260191.59660.6500195290151.640−12500200280201.640−16500226264101.5681020500200283171.634060500238250121.54814200500220270101.5809600500202280181.63202000[b](#tblfn0060){ref-type="table-fn"}50023725581.54215[^43][^44]Table 15Preliminary Cytotoxicity Assay Using ClearTaste in the Absence of Exogenous Metabolic Activation, 24 h Treatment and 24 h Harvest.Table 15Test ArticleTreatment Condition (μg/mL)Total \# Cells CountedCount/Total Cells \# Nuclei/Cell (1 2 \> 2)CBPI[a](#tblfn0065){ref-type="table-fn"}Cytotoxicity[a](#tblfn0065){ref-type="table-fn"} (%)Water500150270801.860ClearTaste0.2500145258971.904−50.6500178248741.79282500193235721.758126500198218841.7721020500188223891.802760500212217711.71817200500203240571.70818600500217240431.652242000[b](#tblfn0070){ref-type="table-fn"}500238213491.62228[^45][^46]

### 3.2.2. Micronucleus assay {#sec0190}

Results from the micronucleus assay for individual exposure groups are shown in [Table 16](#tbl0080){ref-type="table"}, [Table 17](#tbl0085){ref-type="table"}, [Table 18](#tbl0090){ref-type="table"}. These tables show the average percent of micronucleated cells per dose under varying conditions of exogenous metabolic activation and treatment/harvest times. The data show ClearTaste's ability to induce micronuclei formation was not statistically significant though was for each positive control.Table 16Micronucleus Analysis of HPBLs Treated with ClearTaste in the Absence of Exogenous Metabolic Activation, Definite Assay: 4 h Treatment and 24 h Harvest.Table 16Test ArticleTreatment Conditions (μg/mL)Replicate Culture IdentifierTotal \# of Cells/Culture (%)Micronucleated Binucleated Cells/Culture (%)Micronucleated Binucleated Cells/Dose (average%)WaterA10000.30.3B10000.3ClearTaste250A10000.30.4B10000.4500A10000.20.3B10000.31000[a](#tblfn0075){ref-type="table-fn"}A10000.30.3B10000.3[^47]Table 17Micronucleus Analysis of HPBLs Treated with ClearTaste in the Presence of Exogenous Metabolic Activation, Definitive Assay: 4 h Treatment and 24 h Harvest.Table 17Test ArticleTreatment Conditions (μg/mL)Replicate Culture IdentifierTotal \# of Cells/Culture (%)Micronucleated Binucleated Cells/Culture (%)Micronucleated Binucleated Cells/Dose (average%)WaterA10000.30.3B10000.2ClearTaste250A10000.30.3B10000.3500A10000.30.4B10000.41000[a](#tblfn0080){ref-type="table-fn"}A10000.40.4B10000.3Cyclophosphamide5A10001.31.7[b](#tblfn0085){ref-type="table-fn"}B10002.0[^48][^49]Table 18Micronucleus Analysis of HPBLs Treated with ClearTaste in the Absence of Exogenous Metabolic Activation, Definitive Assay: 24 h Treatment and 24 h Harvest.Table 18Test ArticleTreatment Conditions (μg/mL)Replicate Culture IdentifierTotal \# of Cells/Culture (%)Micronucleated Binucleated Cells/Culture (%)Micronucleated BinucleatedCells/Dose (average%)WaterA10000.50.5B10000.5ClearTaste500A10000.40.3B10000.21000A10000.20.3B10000.32000A10000.20.3B10000.3Vinblastine7.5 × 10^−3^A10001.11.6[a](#tblfn0090){ref-type="table-fn"}B10002.1[^50]

4. Discussion {#sec0195}
=============

The results of the bacterial reverse mutation assay indicate that under any of the conditions analyzed ClearTaste did not cause a positive mutagenic response. The results are clear on the matter based on the evaluation criteria. A deeper look at the data shows that ClearTaste does not broach mutagenicity under any experimental circumstance with any average revertant count developed from the data being much lower than the threshold required to confirm mutagenicity.

The results of the micronucleus assay indicate that ClearTaste does not induce micronuclei formation when exposed to HPBLs *in vitro* according to cytotoxicity and statistical comparisons of mononucleated cell development. It can be concluded that ClearTaste poses neither mutagenic nor genotoxic safety issues.

The results displayed and discussed herein indicate that ClearTaste as manufactured by MycoTechnology is safe for incorporation into the food supply according to its intended use, typically at \<50 and up to 1000 ppm, in view of the qualities tested. These results are not necessarily to be expected given that some mushrooms are mutagenic and others not \[[@bib0075]\].While *C*. *sinensis* is not discussed in the referenced study, the study implies that fungal material should be assessed for mutagenic and genotoxic potential to be sure of these safety considerations.

Positive results in either assay could indicate the presence of aflatoxin \[[@bib0080]\], though not all mycotoxins register as mutagens in such assays, as some will only register as mutagenic under certain exogenous metabolic activation systems \[[@bib0080], [@bib0085]\]. It is not surprising that no sign of mycotoxin was found as *C*. *sinensis* has never been reported to create any mycotoxin but given the complexities involved in mutagenesis and genotoxicity it should still be required to conduct such tests to decisively conclude that a novel foodstuff, even in view of literature generally conferring safety to related items, isn't mutagenic or genotoxic according to the parameters of GLP reverse mutation and micronucleus assays \[[@bib0090], [@bib0095], [@bib0100], [@bib0105], [@bib0110]\]. The present study continues to confer safety to products derived from *C*. *sinensis*.

The authors submit that to fully understand the nature of ClearTaste's safety, studies regarding non-genotoxic mechanisms of carcinogenesis should be conducted to finalize comprehension of ClearTaste's full carcinogenic potential \[[@bib0115], [@bib0120], [@bib0125]\]. With that consideration it is understood that most carcinogenic compounds are mutagenic/genotoxic. According to the literature the work herein addresses ∼90% of possible carcinogens with the Ames test alone, constituting an important contribution in confirming important aspects of ClearTaste's safety \[[@bib0095]\].
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[^1]: Done according to EPA method SW9045C.

[^2]: All values not done by difference conducted according to AOAC methods at Certified Labs, Inc.

[^3]: 95% CL = mean ± 2 SD (but not less than zero).

[^4]: Positive control for non-activated 4 h studies is Mitomycin C, Positive control for activated 24 hour study is Vinblastine.

[^5]: Range is from minimum to maximum.

[^6]: Positive control for S9 activated studies is cyclophosphamide.

[^7]: Range is from minimum to maximum.

[^8]: The numerical marking '1′ indicates normal background.

[^9]: The abbreviation 'NP' indicates non-interfering particulate.

[^10]: The superscript marking '^A^' indicates an automatic count.

[^11]: The numerical marking '1′ indicates normal background.

[^12]: The abbreviation 'NP' indicates non-interfering particulate.

[^13]: The superscript marking '^A^' indicates an automatic count.

[^14]: The numerical marking '1′ indicates normal background.

[^15]: The abbreviation 'NP' indicates non-interfering particulate.

[^16]: 2NF is 2-nitrofluorene.

[^17]: SA is sodium azide.

[^18]: 9AAD is 9-aminoacridine.

[^19]: MMS is methyl methanesulfonate.

[^20]: The superscript marking '^A^' indicates an automatic count.

[^21]: ^\*^The superscript marking '^A^' indicates an automatic count.

[^22]: The numerical marking '1′ shown after the automatic count indicates normal background.

[^23]: The abbreviation 'NP' indicates non-interfering particulate.

[^24]: 2AA is 2-aminoanthracene.

[^25]: The numerical marking '1′ indicates normal background.

[^26]: The abbreviation 'NP' indicates non-interfering particulate.

[^27]: 2NF is 2-nitrofluorene.

[^28]: SA is sodium azide.

[^29]: 9AAD is 9-aminoacridine.

[^30]: MMS is methyl methanesulfonate.

[^31]: The superscript marking '^A^' indicates an automatic count.

[^32]: ^\*^The superscript marking '^A^' indicates an automatic count.

[^33]: The numerical marking '1′ indicates normal background.

[^34]: The abbreviation 'NP' indicates non-interfering particulate.

[^35]: 2NF is 2-nitrofluorene.

[^36]: SA is sodium azide.

[^37]: 9AAD is 9-aminoacridine.

[^38]: MMS is methyl methanesulfonate.

[^39]: ^a^CBPI (Cell Block Proliferation Index) and cytotoxicity are calculated by the following equations:

[^40]: $CBPI = \frac{\left( 1 \right)\left( {mononucleatedcells} \right) + \left( 2 \right)\left( {binucleatedcells} \right) + \left( 3 \right)\left( {multinucleatedcells} \right)}{Totalcellsscored}$.

[^41]: $Cytotoxicity = 100 - 100\left( \frac{CBPI_{water} - 1}{CBPI_{ClearTaste} - 1} \right)$.

[^42]: ^b^Visible precipitate was observed in the treatment medium at the conclusion of the treatment period.

[^43]: See [Table 7](#tbl0035){ref-type="table"} for CPBI and cytotoxicity equations.

[^44]: Visible precipitate was observed in the treatment medium at the conclusion of the treatment period.

[^45]: See [Table 7](#tbl0035){ref-type="table"} for CPBI and cytotoxicity equations.

[^46]: Visible precipitate was observed in the treatment medium at the conclusion of the treatment period.

[^47]: Visible precipitate was observed in the treatment medium at the conclusion of the treatment period.

[^48]: Visible precipitate was observed in the treatment medium at the conclusion of the treatment period.

[^49]: p ≤ 0.01, Fisher's exact test, relative to water.

[^50]: Visible precipitate was observed in the treatment medium at the conclusion of the treatment period.
